Pilot Phase II Study of Sandostatin LAR in Patients with Advanced Hepatocellular Carcinoma to assess toxicity and improve survival
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Octreotide (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics; Therapeutic Use
- 08 May 2009 Status changed from completed to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 06 Nov 2007 Status change
- 06 Nov 2007 New trial record.